Described as having never ending poison ivy, atopic dermatitis is a constant annoyance that many people have to live with, especially those who are predisposed to asthma and hay fever. Upon the recent conclusion of its phase IIb trial, the injectable drug duplimumab has shown promise in reducing the severity of eczema. Improvement ranged from 74% – 45%, compared to the 18% reported with placebo. Separate clinical trials have also shown efficacy of managing asthma, cutting episodes down by 87%. Duplimumab is the first drug of its kind, and it is expected to begin late-stage trials later in the year. How do you typically help your patients using injectable medications to remain adherent?
For additional information please visit Reuters
Image courtesy of [Sura Nualpradid]/FreeDigitalPhotos.Net